VANOBID Drug Patent Profile
✉ Email this page to a colleague
When do Vanobid patents expire, and what generic alternatives are available?
Vanobid is a drug marketed by Sanofi Aventis Us and is included in two NDAs.
The generic ingredient in VANOBID is candicidin. There are four drug master file entries for this compound. Additional details are available on the candicidin profile page.
Summary for VANOBID
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 7 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VANOBID at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for VANOBID
US Patents and Regulatory Information for VANOBID
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | VANOBID | candicidin | OINTMENT;VAGINAL | 061596-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | VANOBID | candicidin | TABLET;VAGINAL | 061613-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |